Low platelet count and elevated serum thrombopoietin after severe trauma

European Journal of Haematology

Volumn 64, Issue 3, 2000, Pages 157-163

  Hobisch Hagen, Petra ^a   Jelkmann, Wolfgang ^b   Mayr, Andreas ^a   Wiedermann, Franz ^a   Fries, Dietmar ^a   Herold, Manfred ^a   Klingler, Anton ^c   Schobersberger, Wolfgang ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Platelets; Thrombopoietin; Trauma; Vascular endothelial growth factor

Indexed keywords

INTERLEUKIN 6; THROMBOPOIETIN; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; MALE; MULTIPLE TRAUMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; THROMBOCYTE ADHESION; THROMBOCYTE COUNT;

ADULT; ENDOTHELIAL GROWTH FACTORS; FEEDBACK; FEMALE; HUMANS; INTERLEUKIN-6; LYMPHOKINES; MALE; MIDDLE AGED; MULTIPLE TRAUMA; PLATELET COUNT; THROMBOCYTOPENIA; THROMBOPOIETIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034016427     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.90102.x     Document Type: Article

References (33)

1. 1. KAUSHANSKY K. Thrombopoietin. N Engl J Med 1998;10: 746-754.
2. 2. DE SAUVAGE FJ, CARVER-MOORE K, LUOH SM, RYAN A, DOWD M, EATON DL, MOORE MW. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996;183:651-656.
3. 3. WENDLING F, MARASKOVSKY E, DEBILI N, et al. c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369:571-574.
4. 4. VIGON I, MORNON J-P, COCAULT, MITJARILA MT, TAMBOURIN P, GISSELBRECHT S, SOUYRI M. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992;89:5640-5644.
5. 5. SUNGARAN R, MARKOVIC B, CHONG BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997;89:101-107.
6. 6. NICHOL JL, HOKOM MM, HORNKOHL A, et al. Megakaryocyte growth and development factor. J Clin Invest 1995;95: 2973-2978.
7. 7. MARSH JCW, GIBSON FM, PRUE RL, et al. Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol 1996;95:605-610.
8. 8. EMMONS RVB, REID DM, COHEN RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068-4071.
9. 9. BROUDY VC, LIN NL, SABATH DF, PAPAYANNOPOULOU T, KAUSHANSKY K. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997;89:1896-1904.
10. 10. DETTKE M, IMHOF M, EXNER M, KURZ M, HÖCKER P. Increased level of thrombopoietin during consumptive coagulopathy. Thromb Haemost 1998;79:238-239.
11. 11. HOBISCH-HAGEN P, SCHOBERSBERGER W, LUZ G, INNERHOFER P, JELKMANN W. Circulating immunoreactive thrombopoietin increases rapidly after normovolemic hemodilution. Thromb Haemost 1998;80:718-719.
12. 12. BOBIK R, HONG Y, BREIER G, MARTIN JF, ERUSALIMSKY JD. Thrombopoietin stimulates VEGF release from c-Mpl-expressing cell lines and haematopoietic progenitors. FEBS Lett 1998;432:10-14.
13. 13. FERRARA N, DAVIS-SMYTH T. The biology of vascular endothelial growth factor. Endocrine Rev 1997;18:4-25.
14. 14. BATTEGAY EJ. Angiogenesis: mechanistic insights, neovascular diseases and therapeutic prospects. J Mol Med 1995; 73:333-346.
15. 15. GRAD S, ERTEL W, KEEL M, INFANGER M, VONDERSCHMITT DJ, MALY FE. Strongly enhanced serum levels of vascular endothelial growth factor (VEGF) after polytrauma and burn. Clin Chem Lab Med 1998;36:379-383.
16. 16. MINCHENKO A, BAUER T, SALCEDA S, CARO J. Hypoxia stimulation of vascular endothelial growth factor expression in vivo and in vitro. Lab Invest 1994;71:374-379.
17. 17. SHWEIKI D, ITIN A, SOFFER D, KESHET E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
18. 18. COHEN T, NAHARI D, CEREM LW, NEUFELD G, LEVI BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-741.
19. 19. HOCH R, RODRIGUEZ R, MANNING T, BISHOP M, MEAD P, SHOEMAKER WC, ABRAHAM E. Effects of accidental trauma on cytokine and endotoxin production. Crit Care Med 1993;21: 839-845.
20. 20. SVOBODA P, KANTOROVA I, OCHMAN J. Dynamics of interleukin 1, 2, and 6 and tumor necrosis factor alpha in multiple trauma patients. J Trauma 1994;36:336-340.
21. 21. BAKER SP, ONEILL B, HADON W, LONG WB. The injury severity score: A method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974; 14:187-196.
22. 22. HEITS F, KATSCHINSKI DM, WIEDEMANN GJ, WEISS CH, JELKMANN W. Serum vascular endothelial growth factor (VEGF), a prognostic indicator in sarkoma and carcinoma patients. Int J Oncol 1997;10:333-337.
23. 23. HEITS F, KATSCHINSKI DM, WILMSEN U, WIEDEMANN GJ, JELKMANN W. Serum thrombopoietin and interleukin 6 concentrations in tumour patients and response to chemotherapy-induced thrombocytopenia. Eur J Haematol 1997; 59:53-58.
24. 24. USUKI K, TAHARA T, IKI S, et al. Serum thrombopoietin level in various hematological diseases. Stem Cells 1996;14:558-565.
25. 25. COHEN-SOLAL K, VILLEVAL JL, TITEUX M, LOK S, VAINCHENKER W, WENDLING F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996;88:2578-2584.
26. 26. STOFFEL R, WIESTNER A, SKODA RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87:567-573.
27. 27. KOSUGI S, KURATA Y, TOMIYAMA Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996;93:704-706.
28. 28. KUTER DJ, ROSENBERG RD. Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood 1994;84: 1464-1472.
29. 29. KUTER DJ, ROSENBERG RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720-2730.
30. 30. FIELDER PJ, GURNEY AL, STEFANICH E, MARIAN M, MOORE MW, CARVER-MOORE K, dE SAUVAGE FJ. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996;87:2154-2161.
31. 31. NAGATA Y, SHOZAKI Y, NAGAHISA H, NAGASAWA T, ABE T, TODOKORO K. Serum thrombopoietin is not regulated by transcription but by the total count of both megacaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost 1997;77:808-814.
32. 32. BROWN LF, YEO KT, BERSE B, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992;176:1375-1379.
33. 33. FRANK S, HÜBNER G, BREIER G, LONGAKER MT, GREENHALGH DG, WERNER S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1996; 270:12607-12613.